DBP International AB: investigators’ meeting for the SI-053 Phase I study was held
Double Bond Pharmaceutical AB (publ) (“DBP”) has yesterday hosted an investigators’ meeting for the planned SI-053 Phase I study. This is an open label dose escalation and dose expansion study, to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and recommended Phase 2 Dose of SI-053 and the first-patient-in is expected to be enrolled during the second quarter of 2021. The meeting gathered investigators from 4 clinics in 2 countries together with the Clinical Trial Team from DBP and key personnel from the contract research organization (CRO) CATO-SMS